| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1111243253 |
| P356 | DOI | 10.1186/S13075-018-1779-5 |
| P932 | PMC publication ID | 6323669 |
| P698 | PubMed publication ID | 30616644 |
| P50 | author | Yair Molad | Q89678462 |
| P2093 | author name string | Elisheva Pokroy-Shapira | |
| Shirly Oren | |||
| Yonatan Edel | |||
| Ariela Dortort Lazar | |||
| Mohammad Egbaria | |||
| Vitaly Kliminski | |||
| Yael Pri-Paz Basson | |||
| P2860 | cites work | High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II | Q22254095 |
| Triggering receptor expressed on myeloid cells receptor family modulators: a patent review | Q26999265 | ||
| Pathogen recognition and innate immunity | Q27861084 | ||
| TREM-1 amplifies inflammation and is a crucial mediator of septic shock | Q28185818 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Cutting edge: expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia | Q28297321 | ||
| A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group | Q29614889 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future | Q33546571 | ||
| Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. | Q33967600 | ||
| The pathogenesis of the antiphospholipid syndrome | Q34332601 | ||
| A role for Toll-like receptor mediated signals in neutrophils in the pathogenesis of the anti-phospholipid syndrome | Q34364580 | ||
| Differential regulation of proinflammatory mediators following LPS- and ATP-induced activation of monocytes from patients with antiphospholipid syndrome. | Q35133146 | ||
| TREMs in the immune system and beyond | Q35140795 | ||
| Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies | Q36013878 | ||
| The TREM receptor family and signal integration | Q36655903 | ||
| The TREM-1/DAP12 pathway | Q37055878 | ||
| Pathogenesis of antiphospholipid syndrome: understanding the antibodies | Q37873720 | ||
| TREM-1: intracellular signaling pathways and interaction with pattern recognition receptors | Q38056337 | ||
| Emerging roles for triggering receptor expressed on myeloid cells receptor family signaling in inflammatory diseases | Q38170160 | ||
| Clinical Association of a Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) in Patients with Systemic Lupus Erythematosus. | Q38896039 | ||
| β₂-glycoprotein I: a novel component of innate immunity. | Q39567484 | ||
| Toll-like receptor (TLR)-4 mediates anti-β2GPI/β2GPI-induced tissue factor expression in THP-1 cells | Q39629773 | ||
| A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis | Q42092652 | ||
| Soluble triggering receptor expressed on myeloid cells-1 is a biomarker of anti-CCP-positive, early rheumatoid arthritis | Q42475068 | ||
| A longitudinal assessment of the natural rate of decline in renal function with age. | Q44221820 | ||
| Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis. | Q46173307 | ||
| Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease? | Q46309832 | ||
| Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome | Q47311173 | ||
| Innate immune response gene expression profiles characterize primary antiphospholipid syndrome. | Q47743642 | ||
| Serum soluble triggering receptor on myeloid cells-1 (sTREM-1) is elevated in systemic lupus erythematosus but does not distinguish between lupus alone and concurrent infection | Q47968735 | ||
| Antiphospholipid antibody-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4. | Q48074369 | ||
| Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. | Q51314663 | ||
| β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. | Q51749454 | ||
| Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q53190445 | ||
| Role of Toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome. | Q54336169 | ||
| Triggering Receptor Expressed on Myeloid cells-1: a new player in platelet aggregation. | Q54364223 | ||
| Involvement of IRAKs and TRAFs in anti-β₂GPI/β₂GPI-induced tissue factor expression in THP-1 cells. | Q54562289 | ||
| Anti–β2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts | Q59140753 | ||
| TREM-1: a new regulator of innate immunity in sepsis syndrome | Q73820244 | ||
| C-reactive protein in primary antiphospholipid syndrome | Q79892833 | ||
| Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis | Q80206526 | ||
| Inflammation in patients with lupus anticoagulant and implications for thrombosis | Q81463194 | ||
| Predictive role of hs-C-reactive protein in patients with antiphospholipid syndrome | Q81569473 | ||
| High-sensitivity C-reactive protein: discriminator between patients with primary and secondary antiphospholipid syndrome | Q81992046 | ||
| Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK- | Q82132738 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antiphospholipid syndrome | Q582207 |
| biomarker | Q864574 | ||
| thrombosis | Q261327 | ||
| primary antiphospholipid syndrome | Q63878006 | ||
| P304 | page(s) | 10 | |
| P577 | publication date | 2019-01-07 | |
| P1433 | published in | Arthritis Research and Therapy | Q15757229 |
| P1476 | title | Elevated plasma level of soluble triggering receptor expressed on myeloid cells-1 is associated with inflammation activity and is a potential biomarker of thrombosis in primary antiphospholipid syndrome | |
| P478 | volume | 21 |
Search more.